Answers are grounded in this paper and cite their sources.
Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.
No takes yet. Share an insight, caveat, or question.
Pappas et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: